Ali Siam

Chief Business Officer

Ali Siam is Chief Business Officer of Rubedo Life Sciences, a clinical-stage biotechnology company developing therapeutics that target senescent cells linked to age-related disease, where he leads business development and corporate strategy. He previously served as Chief Business Officer at Celmatix, a platform biotech focused on a first-in-class ovarian-ageing programme, leading multi-target R&D collaborations with Evotec SE and Bayer AG and supporting the company's corporate and portfolio strategy. Before that, as a team leader at L.E.K. Consulting he led corporate strategy, R&D prioritisation, portfolio strategy and due-diligence engagements for biopharma, diagnostics, healthcare-services and institutional-investor clients, and worked in a whitespace innovation team at AbbVie on go-to-market and lifecycle-management strategy. He studied at Boston College.